BioXcel

BioXcel weighs sale, other strategic options as New Haven biotech continues losses

A potential sale is on the table as BioXcel seeks a path forward.

🔒BioXcel sets retention bonuses for executives amid IGALMI regulatory push

New Haven-based BioXcel Therapeutics has approved retention and milestone bonus agreements for senior executives following the company’s recent regulatory push to expand the use of its lead drug, IGALMI.

BioXcel adds chief commercial officer as it prepares to expand agitation drug IGALMI’s reach

BioXcel Therapeutics Inc. has named longtime biopharmaceutical executive Mark Pavao as its acting chief commercial officer, choosing an industry veteran to lead its efforts to expand the reach of its drug IGALMI.

🔒New Haven’s BioXcel weathers turmoil to regain footing and market confidence

New Haven's BioXcel overcame setbacks and near-delisting to ring Nasdaq's bell again. Its anti-agitation drug now targets home use.
- Advertisement -
Get our email newsletters

Stay up-to-date on the companies, people and issues that impact businesses in Hartford and beyond.

Sign Up Now
ADVERTISEMENT

Latest Stories

More Business News

Movers & Shakers

More Movers & Shakers | Submit an Announcement
ADVERTISEMENT

Thought Leadership

More Thought Leadership

Career Opportunities

More Jobs | Submit a Job

Upcoming Events

View Calendar
More Events | Submit an Event